Document:

<PAGE>

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                                Exhibit No. 10.21
                             DISTRIBUTION AGREEMENT

         AGREEMENT dated as of October 18, 2002 between MATRITECH, INC., a
Delaware corporation, having its principal place of business at 330 Nevada
Street, Newton, Massachusetts 02460, U.S.A. ("MATRITECH") and CYTOGEN
CORPORATION, a Delaware corporation having its principal place of business at
650 College Road East, Princeton, New Jersey 08540 ("CYTOGEN").

                                  INTRODUCTION

         1.       MATRITECH has developed a version of its NMP22(R)Test Kit for
bladder cancer known as BladderChek(TM).

         2.       CYTOGEN desires to become the exclusive distributor for
BladderChek(TM)within the Field in the Territory, as defined below.

         3.       In consideration of the mutual covenants and promises
contained in this Agreement and other good and valuable consideration, MATRITECH
and CYTOGEN agree as follows:

                             ARTICLE I - DEFINITIONS

         As used in this Agreement, the following terms, whether used in the
singular or plural, shall have the following meanings:

         1.1      "Affiliate" means, with respect to any entity, any
corporation, company, partnership, joint venture and/or firm which controls, is
controlled by or is under common control with such entity. For purposes of this
Section 1.1, "control" shall mean (a) in the case of corporate entities, direct
or indirect ownership of at least fifty percent (50%) of the stock or shares
entitled to vote for the election of directors; and (b) in the case of
non-corporate entities, direct or indirect ownership of at least fifty percent
(50%) of the equity interest with the power to direct the management and
policies of such non-corporate entities.

         1.2      "Effective Date" means the date of execution of this
Agreement.

         1.3      "FDA" means U.S. Food and Drug Administration.

         1.4      "Field" means the market for the Product comprised of
urologists, oncologists and end users including group purchase and /or managed
care organizations for the diagnosis and

<PAGE>

                                     - 2 -

management of bladder cancer; provided, such end users have a relationship with
urologists and oncologists with regard to purchase of the Product by such
urologists and oncologists.

         1.5      "Product" means MATRITECH's non-instrumented, single test,
qualitative NMP22 (R) test for bladder cancer known as BladderChek(TM) including
any enhanced, improved or modified version of BladderChek. A unit of Product is
one BladderChek test.

         1.6      "Technical Information" means all scientific and engineering
data owned by MATRITECH or which MATRITECH has the right to use, patentable or
otherwise, relating to the Product, including without limitation, technology
licensed or sublicensed to MATRITECH; all inventions, cell sources, cultures,
strains, organisms and parts thereof; antibodies, clones, plasmids, vectors,
progeny, derivatives and parts thereof; formulae; classes, sources and clone
numbers of antibodies; methods, procedures and processes; materials and
reagents; components, equipment, equipment design, animal studies, clinical or
other evaluations, analytical results, and quality control or other safety
procedures in each case relating to the production, use or manufacture of the
Product.

         1.7      "Term" shall have the meaning set forth in Section 8.1

         1.8      "Territory" means the United States of America, including the
50 states, Puerto Rico, U.S. Virgin Islands and Washington, D.C., but excluding
all other territories and possessions.

         1.9      "CYTOGEN's Net Sales" shall mean amounts invoiced to customers
of CYTOGEN excluding returns and product allowances, free samples, shipping,
taxes, insurance and handling.

                            ARTICLE II - THE PRODUCT

         2.1      Commercialization. CYTOGEN shall exert commercially reasonable
efforts, at its own expense, to:

         (a)      market and promote the Product in the Territory (taken as a
whole) on a diligent commercial basis after the Effective Date;

         (b)      provide an adequate level of customer service including,
without limitation, rendering prompt and willing service with respect to the
Product and handling all customer inquiries with reasonable assistance of
MATRITECH in a manner consistent with the prevailing practices in the industry;

<PAGE>

                                     - 3 -

         (c)      obtain approvals from third-party payors for reimbursement,
with the reasonable assistance of MATRITECH, for the use of the Product within
the Field; and

         (d)      allocate no less than [**]% of its sales force time which
shall not be less than [**] FTEs (full time equivalent employees) , to the
ongoing promotion and sales of the Product for the Term of this Agreement.

         2.2      Compliance with Laws. In performing this Agreement, each of
the parties agree that it will comply in all material respects with applicable
governmental laws, rules, regulations and policies and will hold the other party
harmless and indemnify the other party from the failure to do so. Repeated
non-compliance by a party or its employees or Affiliates with this Section 2.2
shall be deemed to constitute a material, irremediable breach of the terms of
this Agreement, justifying immediate termination under Section 8.2(a)(iii)
hereof.

         2.3      Clinical Marketing, Technical Services. MATRITECH shall
provide assistance to CYTOGEN with clinical marketing of the Product during the
Term of this Agreement, including, without limitation, those activities that
define and support clinical usage. MATRITECH will provide reasonable technical
support services , at its own expense, in furtherance of CYTOGEN's sales efforts
at CYTOGEN'S request.

         2.4      Loss of Exclusivity. If CYTOGEN only purchases between [**]%
and [**]% of the Minimum Purchase Commitment as specified in Section 4.2 of this
Agreement in any given year, MATRITECH shall, as its sole and exclusive remedy,
have the right to, in its sole discretion and upon written notice to CYTOGEN,
renegotiate the terms of the Agreement with CYTOGEN; provided, both parties must
agree to such renegotiated terms in writing or convert CYTOGEN's Marketing
Rights (as defined below) to non-exclusive for the Product within the Field in
the Territory. In the event MATRITECH converts CYTOGEN's Marketing Rights to
non-exclusive for the Field, it must first offer Cytogen similar deal terms if
it intends to offer said Marketing Rights to another person or entity. Failure
by CYTOGEN to purchase at least [**]% of the Minimum Purchase Commitment of
Product as specified in Section 4.2 of this Agreement in any given year shall
result, after prior written notice to CYTOGEN and at MATRITECH's option as
MATRITECH's sole and exclusive remedy, in a) the termination of the Agreement as
provided in Section 8.2(b); provided, however, if MATRITECH terminates this
Agreement under such circumstances, CYTOGEN's sole liability to MATRITECH is
listed in Section 8.3 and 8.4 (with

<PAGE>

                                     - 4 -

CYTOGEN having no liability for breach of CYTOGEN's Minimum Purchase Commitment
under this Agreement), b) a loss of the exclusivity granted under this
Agreement, or c) may attempt to negotiate new terms of the Agreement with
CYTOGEN that may or may not include a loss of exclusivity. In the event of a
loss of exclusivity under this section, CYTOGEN shall no longer have a Minimum
Purchase Commitment for that year and for subsequent years, if any, as set forth
in Section 4.2. If during the Term of this Agreement, CYTOGEN purchases in
excess of [**]% of the Minimum Purchase Commitment, CYTOGEN shall be deemed in
conformance with Section 4.2(a) and shall retain its exclusivity for such
particular period.

         2.5      FDA Clearance. Subject to the terms and conditions contained
in this Agreement, MATRITECH agrees to exert commercially reasonable efforts to
seek, as soon as practicable, diagnosis clearance from the FDA for the Product
in the Territory. Diagnosis clearance shall mean approval by the FDA to use the
Product for the diagnosis of bladder cancer on patients other than those with
reoccurring bladder cancer. MATRITECH shall promptly notify CYTOGEN in writing
in the event MATRITECH does not obtain diagnosis clearance from the FDA.

             ARTICLE III - MARKETING FEE AND INITIAL PURCHASE ORDER

         3.1      Marketing Fees. In consideration of the grant of the Marketing
Rights set forth in this Agreement, CYTOGEN shall pay to MATRITECH $150,000 as a
marketing fee upon the Effective Date.

         3.2      Initial Purchase Order. CYTOGEN shall attach to this Agreement
an irrevocable purchase order for [**]% of the Minimum Purchase Commitment for
calendar years 2002 and 2003 (the "Initial Purchase Order"). The Initial
Purchase Order shall be for [**] units at $[**] per unit. MATRITECH shall
deliver [**] units of the Initial Purchase Order on or before October 31, 2002
and the remainder by no later than December 31, 2002.

                          ARTICLE IV - MARKETING RIGHTS

         4.1      Marketing Rights. CYTOGEN shall have the exclusive right to
sell or otherwise distribute the Product in the Territory within the Field
("Marketing Rights"). CYTOGEN shall not sell or otherwise distribute the Product
to any person or entity in the Territory if CYTOGEN has reason to believe that
such person or entity intends to resell or redistribute the Product outside of
the Territory or the Field. The rights granted herein shall not be construed to
confer

<PAGE>

                                     - 5 -

any license rights upon CYTOGEN, by implication, estoppel or otherwise, to use
or practice any of MATRITECH's patents or other intellectual property or use any
Technical Information. If and to the extent that CYTOGEN performs its rights and
obligations under this Agreement, including, without limitation, its Marketing
Rights, through an Affiliate, CYTOGEN shall cause such Affiliate to be bound in
writing by all the terms and conditions of this Agreement. MATRITECH shall not
sell or otherwise distribute the Product to any person or entity if MATRITECH
has reason to believe that such person or entity intends to resell or
redistribute the Product within the Field in the Territory. Subject to Section
8.4, MATRITECH and its licensee(s) reserve the right to market and sell other
non-point of care formats of the NMP22 test within the Field in the Territory
solely to professional laboratories, such as automated formats designed for such
professional laboratories.

         4.2      Sales Price and Minimum Purchase Commitment.

         (a)      CYTOGEN shall purchase from MATRITECH during each year of this
Agreement the minimum number of units of the Product set forth under "Minimum
Purchase Commitments" in the table below.

<TABLE>
<CAPTION>
----------------------------------
                  MINIMUM PURCHASE
                    COMMITMENTS
CALENDAR YEAR     (TESTS PER YEAR)
----------------------------------
<S>               <C>
2002
2003                   [**]
----------------------------------
2004                   [**]
----------------------------------
2005                   [**]
----------------------------------
2006                   [**]
----------------------------------
2007                   [**]
----------------------------------
</TABLE>

                  The foregoing Minimum Purchase Commitments will be
renegotiated by CYTOGEN and MATRITECH if the FDA does not approve use of the
Product for diagnosis by the end of the second calendar quarter of 2003 as
follows: the Minimum Purchase Commitments will be adjusted downward to reflect
any FDA delay in providing clearance for the use of the Product for diagnosis.
If MATRITECH does not receive FDA approval for the use of the Product for
diagnosis [**] the annual Minimum Purchase Commitment for the year in which
approval is granted and for previous years shall be immediately reduced by [**]

<PAGE>

                                     - 6 -

         (b)      The base price per unit of Product shall be fixed at $[**] per
unit F.O.B. MATRITECH's place of manufacture or supply (the "Base Price").
Commencing in 2004 and continuing for the Term of the Agreement, the price per
unit of Product will be the Base Price plus [**]% of CYTOGEN's Net Sales of the
Product. CYTOGEN shall tender payment to MATRITECH of the [**]% payments of
CYTOGEN's Net Sales on a quarterly basis no more than 30 days after the end of
each calendar quarter. Commencing in 2004, and provided that the prior year's
actual purchases by CYTOGEN exceed that year's Minimum Purchase Commitment, the
price per unit of Product will be calculated as set forth in the table below:

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------
 PRIOR YEAR'S ACTUAL PURCHASES
RELATIVE TO THAT YEAR'S MINIMUM
      PURCHASE COMMITMENT                               PRODUCT PRICE
-------------------------------------------------------------------------------------
<S>                                       <C>
>[**]% to [**]%                           [**]% off Base Price plus payment to
                                          Matritech of [**]% of CYTOGEN's Net Sales
                                          of the Product
-------------------------------------------------------------------------------------
>[**]% to [**]%                           [**]% off Base Price plus payment to
                                          Matritech of [**]% of CYTOGEN's Net Sales
                                          of the Product
-------------------------------------------------------------------------------------
>[**]%                                    [**]% off Base Price plus payment to
                                          Matritech of [**]% of CYTOGEN's Net Sales
                                          of the Product
-------------------------------------------------------------------------------------
</TABLE>

                  For example, if CYTOGEN purchases [**] units of Product in
2004, then the Base Price for 2005 shall be $[**] ([**]% discount off $[**])
plus [**]% of CYTOGEN's Net Sales.

         (c)      After 2003, the Base Price may be renegotiated once per
calendar year commencing in 2004, but only if the Council of Medical Services
reimbursement to the end user changes more than [**]% (upward or downward) from
the then current amount.

         4.3      Terms and Conditions. All orders of Product by CYTOGEN from
MATRITECH during the term of this Agreement shall be subject to the terms and
conditions of this Agreement and shall be subject to acceptance by MATRITECH, as
set forth in Section 4.4 below, except with respect to orders to satisfy Minimum
Purchase Commitments which MATRITECH shall be

<PAGE>

                                     - 7 -

obligated to accept. Nothing contained in any purchase order or similar document
submitted by CYTOGEN to MATRITECH shall in any way modify or add to the terms
and conditions contained in this Agreement. Invoices are payable within [**]
after the date of invoice.

         4.4      Order and Acceptance.

         (a)      All orders for Product submitted by CYTOGEN shall be initiated
by written orders sent to MATRITECH and requesting a delivery date during the
term of this Agreement. Any order initially placed orally or by e-mail must be
confirmed in writing.

         (b)      To facilitate MATRITECH's production scheduling, CYTOGEN shall
submit purchase orders to MATRITECH at least [**] days prior to the requested
date of delivery. Except with respect to orders to fulfill the Minimum Purchase
Commitment requirements set forth above, no order shall be binding upon
MATRITECH until accepted by MATRITECH in writing, and MATRITECH shall have no
liability to CYTOGEN with respect to purchase orders that are not accepted.
MATRITECH reserves the right to allocate the supply of the Product pro rata,
based approximately on the relative numbers of Product ordered, without
incurring any liability to CYTOGEN for commissions, damages or otherwise.
MATRITECH shall notify CYTOGEN of the acceptance or rejection of an order and of
the assigned delivery date for accepted orders within fifteen (15) days of
receipt of an order from CYTOGEN. No partial shipment of an order shall
constitute the acceptance of the entire order, absent the written acceptance of
such entire order. MATRITECH shall use its reasonable efforts to deliver the
Product at the times specified either in its quotation or in its written
acceptance of CYTOGEN's orders.

         4.5      Cancellation of Orders. If MATRITECH accepts any cancellation
request made within ten (10) days of the scheduled ship date, CYTOGEN agrees to
bear MATRITECH's restocking fee of up to [**] percent ([**]%) of the total
order.

         4.6      F.O.B. Point, Title and Risk of Loss. All prices are F.O.B.
either MATRITECH's distribution facility or place of manufacturing (the "F.O.B.
Point"). Product shall be purchased at the F.O.B. Point. Title and risk of loss
of such Product shall pass to CYTOGEN at said location. MATRITECH shall provide
CYTOGEN with written invoices for all Product when shipped.

<PAGE>

                                     - 8 -

The foregoing notwithstanding, however, CYTOGEN shall, as between itself and its
customers, be acting as principal and not as an agent of MATRITECH.

         4.7      Returns. CYTOGEN shall have no right of return for Product
purchased hereunder. If, however, any Product fails to perform in accordance
with the labeling provided by MATRITECH as documented by MATRITECH's examination
of the Product pursuant to its formal complaint handling procedure which has
been established in accordance with standard industry practices, CYTOGEN may
return such defective Product but in no case later than one-hundred eighty (180)
days from the original ship date from MATRITECH to CYTOGEN. MATRITECH shall keep
CYTOGEN appraised of its examination of the Product pursuant to its formal
complaint handling procedures and shall provide CYTOGEN with its finding and
shall provide the basis of its determination in the event that MATRITECH finds
that the Product is NOT defective. CYTOGEN shall have the opportunity to raise
reasonable objections to the methods used during and shall have an opportunity
to verify MATRITECH's findings for a period five (5) business days after
MATRITECH's determination, which MATRITECH shall in good faith consider when
determining if an alternate outcome is warranted.

         4.8      Payment. MATRITECH shall provide CYTOGEN with an invoice for
each shipment of Product. Invoices shall be issued and dated on or after the
date of shipment of each order. Under no circumstances will an invoice be issued
for Product that has not been shipped. Invoices shall be paid within [**] days
after the date of invoice.

         4.9      Taxes. CYTOGEN's payments for the Product hereunder are
payable in full to MATRITECH without deduction for taxes (including any
withholding tax) or duties. In addition to such amounts, CYTOGEN shall pay sums
equal to taxes (including, without limitation, sales, withholding, value-added
and similar taxes) based on an end-user's use or possession of the Product under
or in accordance with the provisions of this Agreement, but exclusive of United
States federal, state, and local taxes based on MATRITECH's net income.

         4.10     Dollars. All amounts due MATRITECH hereunder shall be
calculated and paid in U.S. dollars.

         4.11     Shipping. All Product delivered pursuant to the terms of this
Agreement shall be suitably packed for shipment in MATRITECH's standard shipping
cartons, marked for shipment

<PAGE>

                                     - 9 -

to CYTOGEN's address set forth above, and delivered to CYTOGEN or its carrier
agent at the F.O.B. Point. If CYTOGEN does not specify a carrier, MATRITECH
shall select the carrier. All freight, insurance, and other shipping expenses
shall be paid by CYTOGEN. CYTOGEN shall also bear all applicable taxes, duties
and similar charges that may be assessed against the Product after delivery to
the carrier at the F.O.B. Point.

         4.12     Late Payment. Any amount not paid within the [**] days after
the date of an invoice, except for those amounts that both parties agree are in
dispute, shall bear interest at the rate of 1.5% per month until paid in full.

         4.13     Records. To the extent available to it, each party shall
maintain quantity, lot numbers, customer names and addresses, and incident
reports for at least two years beyond expiration date of the Product. Each party
shall keep, and shall require all its Affiliates to keep, full, true and
accurate books of accounts and other records that it generates or obtains
containing all information and data which may be necessary to ascertain and
verify the amounts payable hereunder and to satisfy FDA requirements including
recall and to retain such records for at least five (5) years. During the Term
of this Agreement and for a period of five (5) years following its termination,
each party shall have the right from time to time (but no more than once per
calendar year) and upon ten (10) days prior written notice, to inspect, or have
an agent, accountant or other representative inspect, such books, records and
supporting data solely to verify compliance with the first sentence of this
Section 4.14 during normal business hours. The party being audited may require
any of the auditing party's personnel to execute a confidentiality agreement
prior to giving such personnel access to any materials.

         4.14     Marketing Efforts. CYTOGEN shall be responsible for all
marketing, promotion and distribution of Product within the Territory. In
support of this effort, CYTOGEN and MATRITECH shall develop and CYTOGEN shall
implement annual sales and marketing plans to support and effectively promote
the Product. The marketing plan shall include the commitments outlined on
Attachment A to this Agreement. CYTOGEN shall provide customer and technical
services in support of the Product during the Term of this Agreement. During the
Term of this Agreement, MATRITECH will conduct Product specific marketing
campaigns at its own expense and at such times as it shall reasonably determine.

<PAGE>

                                     - 10 -

         4.15     Samples. "Samples" are defined as units of the Product that
cannot be and are not sold to end-users and must be distributed within [**]
months of receipt by CYTOGEN. CYTOGEN shall receive [**] free Samples to be
delivered simultaneously with the Initial Purchase Order of the Product.

         4.16     [**] Forecasts and Sales and Marketing Reports. To facilitate
MATRITECH'S production scheduling, within [**] days after delivery of the
Initial Purchase Order, and [**] days prior to the beginning of each calendar
[**], CYTOGEN shall furnish MATRITECH with a forecast of its Product purchases,
together with requested delivery dates, for the subsequent [**] month period.
Such forecasts by CYTOGEN are estimates and shall not represent purchase
commitments. Together with these [**] forecasts, CYTOGEN shall provide MATRITECH
with a monthly sales and marketing report that includes, but is not limited to,
unit sales, average selling price per unit of Product, dollar sales for the
entire Territory categorized by either state of zip code and the number of
man-years spent by the sales force.

         4.17     Product Inventory. Subject to MATRITECH's fulfillment of its
supply obligations, CYTOGEN shall be responsible for maintaining adequate
inventory of Product to meet consumer demand.

                    ARTICLE V - INTELLECTUAL PROPERTY RIGHTS

         5.1      Patent Rights. MATRITECH owns and possesses or will own and
possess all right, title and interest, or holds a valid license, in and to the
Product and all associated Trademarks (as defined below), and has taken all
necessary action to protect these rights with respect to the U.S. patent rights
in the Product. MATRITECH has not received any notice of any infringement or
misappropriation by, or conflict with the intellectual property rights of, any
third party which would prevent CYTOGEN from using or selling the Product in the
Territory.

         5.2      Infringement Claims. MATRITECH agrees to indemnify and hold
CYTOGEN harmless against any cost, loss, liability, or expense (including
attorneys' fees) arising out of, resulting from or relating to any claim, suit
or proceeding brought against CYTOGEN or MATRITECH based on a claim that the
Product infringes upon any third party intellectual property right (hereinafter
"Infringement Claims"). CYTOGEN agrees that MATRITECH has the right to defend,
or at its option to settle, and MATRITECH agrees, at its own expense to defend
or at its option to settle any Infringement Claims so long as any such
settlement does not

<PAGE>

                                     - 11 -

adversely affect CYTOGEN's rights under this Agreement or requires CYTOGEN to
perform any actions; provided that MATRITECH is notified promptly in writing of
an Infringement Claim and has sole control over its defense or settlement, and
CYTOGEN provides reasonable assistance in the defense of the same.

         5.3      Infringement Cures. Following notice of an Infringement Claim,
or if MATRITECH believes such a claim is likely, MATRITECH may at its sole
expense and option: (a) [**]or (b) [**]or (c) [**]

         5.4      Limitation. Notwithstanding any other provision of this
Agreement, MATRITECH assumes no liability for any Infringement Claims with
respect to any product in or with which the Product may be used in combination,
but not covering the Product standing alone, and MATRITECH shall have no
liability for any Infringement Claim based on CYTOGEN's: (a) use or distribution
of any Product after MATRITECH's written notice that CYTOGEN should cease use or
distribution of such Product due to an infringement claim; or (b) modification
of the Product, or any part thereof, at the request of CYTOGEN or to meet any
specifications provided by CYTOGEN; (c) combination by CYTOGEN of a Product with
another product, if such infringement claim would have been avoided by the
exclusive use of the Product alone; or (d) any trademark infringements involving
any marking or branding not applied by MATRITECH or involving any marking or
branding applied at the request of CYTOGEN. For all infringement claims to which
this Section 5.4 is applicable, CYTOGEN agrees to indemnify and defend
MATRITECH, provided that CYTOGEN is notified promptly in writing of an
infringement claim and has sole control over its defense or settlement, and
MATRITECH provides reasonable assistance in the defense of the same.

         5.5      Entire liability. THE FOREGOING PROVISIONS OF THIS SECTION 5
STATE THE ENTIRE LIABILITY AND OBLIGATIONS OF MATRITECH, AND THE EXCLUSIVE
REMEDY OF CYTOGEN, WITH RESPECT TO ANY ALLEGED INTELLECTUAL PROPERTY
INFRINGEMENT BY THE PRODUCT, OR ANY PART THEREOF.

         5.6      Unauthorized Use. During the Term of this Agreement, either
party shall promptly notify the other party in writing upon discovery of any
unauthorized use or infringement of the Product or any MATRITECH patent,
copyright, trademark or other

<PAGE>

                                     - 12 -

intellectual property rights with respect thereto. MATRITECH shall have the sole
and exclusive right to bring an infringement action or proceeding against a
third party, and, in the event that MATRITECH brings such an action or
proceeding, CYTOGEN shall cooperate and provide full information and assistance
to MATRITECH and its counsel in connection with any such action or proceeding.
MATRITECH may, at its option settle any such action or proceeding so long as any
such settlement does not adversely affect CYTOGEN's rights under this Agreement
or requires CYTOGEN to perform any actions. During the period of any material
unauthorized use or infringement of the Product or any MATRITECH patent,
copyright, trademark or other intellectual property rights with respect thereto
[**]

         5.7      Other Third-Party Claims. Except for Infringement Claims which
MATRITECH is obliged to settle or defend under this Section 5, in addition to
the claims for which CYTOGEN will indemnify MATRITECH pursuant to Section 5.4
above, each of the parties agree to indemnify, defend and hold the other party
harmless against any cost, loss, liability, or expense (including attorneys'
fees) arising out of any third party claim, resulting from or relating to any
(i) breach of this Agreement (including, without limitation, a breach by
MATRITECH of its limited warranty set forth in Section 7.1), (ii) each party's
negligent acts or willful misconduct; and (iii) in MATRITECH's case for any
claims arising out of the use of the Product; provided that the indemnifying
party is notified promptly in writing of the claim, has sole control over its
defense or settlement, and the party seeking indemnification provides reasonable
assistance in the defense of the same. Each party agrees, that it will not
settle any such claims, unless such settlement does not adversely affect the
other party's rights under this Agreement or requires the indemnified party to
perform any actions.

         5.8      Insurance. Each of the parties have and shall maintain at
least $2 million of insurance with a financially sound carrier subject to
availability on commercially reasonable terms, against any and all losses,
claims, damages and costs which may arise under this Agreement.

         5.9      Identification of Proprietary. All packaging and documentation
for the Product shall include a notation acknowledging MATRITECH's patent rights
in the Product.

<PAGE>

                                     - 13 -

         5.10     Trademarks and Trade Names.

         (a)      The Product shall be sold in the Territory only under the
trademarks, marks and trade names that MATRITECH may adopt from time to time
("Trademarks"). During the term of this Agreement, CYTOGEN shall have the right
to advertise the Product under the Trademarks. CYTOGEN shall not alter or remove
any Trademarks applied at the factory to the Product, packages, labeling or
other materials contained therein. Nothing herein shall grant to CYTOGEN any
right, title or interest in the Trademarks. If during the terms of this
Agreement CYTOGEN challenges (or assists others to challenge) the validity or
ownership of any Trademarks owned by MATRITECH as of the date of this Agreement,
then MATRITECH may by immediate notice to CYTOGEN terminate this Agreement.

         (b)      All representations of the Trademarks that CYTOGEN intends to
use shall first be submitted to MATRITECH for approval, which approval shall not
be unreasonably withheld. CYTOGEN shall promptly provide to MATRITECH for its
review and approval a sample copy of all advertising and promotional materials
prepared by CYTOGEN in connection with the sale of the Product. CYTOGEN shall
develop standard marketing materials including descriptions of the use of the
Product for approval by MATRITECH.

         (c)      Upon termination of this Agreement for any reason, CYTOGEN
shall discontinue the use of MATRITECH's Trademarks.

                      ARTICLE VI - CONFIDENTIAL INFORMATION

         6.1      Treatment of Confidential Information. Each party hereto shall
maintain all confidential or proprietary information of the other party
including, without limitation, all confidential or proprietary Technical
Information, customer lists, pricing, payment amounts, marketing and business
plans and marketing and business strategies ("Confidential Information") in
confidence, and shall not disclose, divulge or otherwise communicate such
Confidential Information to others, or use it for any purpose, except pursuant
to, and in order to carry out, the terms and objectives of this Agreement, and
hereby agrees to exercise every reasonable precaution to prevent and restrain
the unauthorized disclosure of such Confidential Information by any of its
directors, officers, employees, consultants, subcontractors, sublicensees,
agents, or Affiliates. The Confidential Information of each party includes
information about third parties disclosed by one party to this Agreement to the
other party to this Agreement.

<PAGE>

                                     - 14 -

         6.2      Release from Restrictions. The provisions of Section 6.1 shall
not apply to any Confidential Information disclosed hereunder which:

                  (a)      was known or used by the receiving party prior to its
date of disclosure to the receiving party, as evidenced by the prior written
records of the receiving party; or

                  (b)      either before or after the date of disclosure to the
receiving party is lawfully disclosed to the receiving party by an independent,
unaffiliated third party rightfully in possession of the Confidential
Information; or

                  (c)      either before or after the date of the disclosure to
the receiving party becomes published or generally known to the public through
no fault or omission on the part of the receiving party or its Affiliates and
under no obligation of confidentiality; or

                  (d)      is required to be disclosed by the receiving party to
comply with applicable laws, to defend or prosecute litigation or, as provided
herein, to comply with governmental regulations, provided that the receiving
party provides prior written notice of such disclosure to the other party and
takes reasonable and lawful actions to avoid and/or minimize the degree of such
disclosure.

                            ARTICLE VII - WARRANTIES

         7.1      Warranty to End-Users. MATRITECH gives a limited warranty to
CYTOGEN and to the end-users of the Product that the Product conforms to the
labeling supplied by MATRITECH until the date of expiration of the Product.
MATRITECH specifically disclaims (on the part of MATRITECH and its suppliers)
all other conditions, warranties and other terms relating to the Product.
CYTOGEN shall not give (or purport to give) or enter into (or purport to enter
into) on behalf of MATRITECH any representation, condition, warranty or other
term in relation to the Product. CYTOGEN will indemnify MATRITECH against all
liabilities relating to the Product and against all costs and expenses
associated with claims in respect of such liabilities to the extent that the
liabilities result from a breach by CYTOGEN of the terms of the preceding
sentence of this Section 7.1.

         7.2      Disclaimer of Warranty. EXCEPT FOR THE WARRANTY PROVIDED FOR
IN SECTIONS 5.1 AND 7.1 ABOVE, MATRITECH DISCLAIMS ANY AND ALL WARRANTIES OR
CONDITIONS OF ANY KIND WHATSOEVER, EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE,
INCLUDING THOSE FOR MERCHANTABILITY,

<PAGE>

                                     - 15 -

SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE AND/OR AGAINST
INFRINGEMENT, WHICH ARE EXPRESSLY EXCLUDED.

                           ARTICLE VIII - TERMINATION

         8.1      Term. This Agreement shall remain in effect until December 15,
2007, unless earlier terminated in accordance with the provisions of this
Article VIII or pursuant to Section 2.4. The term of this Agreement shall be
renewed for one (1)-year terms upon mutual written consent provided at least
ninety (90) days prior to the end of the term (including any renewal thereof) of
this Agreement.

         8.2      Termination for Breach, etc.

         (a)      Any party not then in default under this Agreement shall be
entitled to terminate this Agreement by written notice to the other party in the
event that the other party shall be in default of any money payment or other
material obligations hereunder, (i) thirty (30) days after notice of any money
payment default if the defaulting party shall have failed to remedy such default
within such 30-day period, (ii) sixty (60) days after notice of any other
default capable of cure, if the defaulting party shall have failed to remedy
such default within such 60-day period, and (iii) immediately upon any breach
that is incapable of cure.

         (b)      In addition, this Agreement may be terminated immediately upon
written notice (i) as provided in Sections 2.2, 2.4 and 8.2(a)(iii) hereof, or
(ii) in case of either party's insolvency, dissolution, termination of existence
or the appointment of a custodian or receiver for such party if such appointment
is not dismissed within thirty (30) days or the institution by such party of a
proceeding in bankruptcy, reorganization, receivership, insolvency or other
similar law affecting the right of creditors proceeding in bankruptcy,
reorganization, receivership, insolvency or other similar law, and if such
proceeding is not dismissed within thirty (30) days of filing.

         8.3      Duties Upon Termination.

         (a)      In the event of the expiration or termination of this
Agreement pursuant to this Article VIII for any reason whatsoever:

                  (i)      CYTOGEN shall cease, as soon as is practicable from
         acting as distributor of the Product and abstain from making further
         sales of the Product;

<PAGE>

                                     - 16 -

                  (ii)     Both parties shall cooperate with each other in
         completing all outstanding obligations to the other, including the
         fulfillment of each warranty term and condition under this Agreement;
         and

                  (iii)    Upon expiration of the three (3) month period after
         termination of this Agreement, CYTOGEN shall not dispose of any Product
         purchased from MATRITECH except to MATRITECH or to a company appointed
         by MATRITECH.

         (b)      No termination or expiration of this Agreement shall relieve
either party of any then-accrued payment, offset or obligation. Any and all such
payments, offsets or other obligations accrued hereunder as of the date of
termination or expiration shall remain due and payable in accordance with the
terms hereof.

         (c)      Notwithstanding any termination or expiration of this
Agreement, the obligations of the parties contained in Articles V, VI, VII, IX
and X and in Sections 3.1, 4.13, and 8.4, and this Section 8.3 with respect to
events occurring prior to the effective date of such termination or expiration,
shall survive and continue to be enforceable.

         (d)      Upon any termination of this Agreement each party shall
promptly return to the other party all written Confidential Information, and all
copies thereof, of the other party or at the discretion of the requested party,
certify that all such Confidential Information has been destroyed. In addition,
if MATRITECH terminates this Agreement due to a material breach by CYTOGEN,
pursuant to the terms in Section 8.2(b), or in the event of termination due to
failure by the parties to consent pursuant to Section 10.2, CYTOGEN shall
deliver to MATRITECH a list of its customers complete with full addresses and
contact information who have purchased the Product within the preceding 24
months and the quantities purchased by them by no later than ten (10) working
days from the date of notice of such termination.

         8.4      Non-Competition. CYTOGEN will be precluded from, directly or
indirectly, selling or marketing a device or product that is competitive with
the Product during the Term of this Agreement and for a period of [**] years
following termination of the Agreement. During the Term of this Agreement,
MATRITECH shall not, directly or indirectly, sell or market a non-instrumented
single test device or product that is competitive with the Product in the Field.

<PAGE>

                                     - 17 -

                      ARTICLE IX - LIMITATION OF LIABILITY

         9.1      Liability Upon Termination. Except as otherwise expressly
provided in this Agreement, in the event of (a) the expiration of this Agreement
in accordance with its terms or (b) the termination by either party in
accordance with any of the provisions of this Agreement, neither party shall be
liable to the other, because of such expiration or termination, for
compensation, reimbursement or damages on account of the loss of prospective
profits or anticipated sales or on account of expenditures, inventory,
investments, leases or commitments in connection with the business or goodwill
of MATRITECH or CYTOGEN. Expiration or termination shall not, however, relieve
either party of obligations incurred prior to the expiration or termination.

         9.2      Liability for Breach. Except as provided in Article V or
Section 6.1, in the event of any breach by MATRITECH of any of its obligations
hereunder, CYTOGEN's sole and exclusive remedy shall be (i) an equitable
adjustment in price of Product subsequently purchased by CYTOGEN, as may be
agreed to by the parties, or (ii) failing any agreement, return to Matritech, at
MATRITECH's expense, of all or any portion of the Product remaining in CYTOGEN's
possession for a refund of the purchase price paid by CYTOGEN, plus all
applicable shipping expenses.

         9.3      Liability for Other Damages. MATRITECH'S TOTAL LIABILITY
ARISING OUT OF THIS AGREEMENT, THE TERMINATION THEREOF, AND/OR SALE OF THE
PRODUCT HEREUNDER, SHALL BE LIMITED TO THE AMOUNT HAVING THEN ACTUALLY BEEN PAID
BY CYTOGEN TO MATRITECH FOR THE PURCHASE OF PRODUCT UNDER THIS AGREEMENT. EXCEPT
FOR PRODUCT SUPPLIED TO CYTOGEN TO REPLACE PRODUCT THAT DOES NOT CONFORM TO
MATRITECH'S LIMITED WARRANTY UNDER SECTION 7.1, IN NO EVENT SHALL MATRITECH BE
LIABLE FOR COSTS OF SUBSTITUTE PRODUCTS. IN NO EVENT SHALL EITHER PARTY BE
LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, MULTIPLE
OR PUNITIVE DAMAGES, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, AND WHETHER
OR NOT FOR BREACH OF CONTRACT, NEGLIGENCE OR OTHERWISE, AND WHETHER OR NOT SUCH
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. THESE LIMITATIONS WILL

<PAGE>

                                     - 18 -

APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY
PROVIDED HEREIN. MATRITECH'S LIMITATION OF LIABILITY IS CUMULATIVE, WITH ALL
MATRITECH'S EXPENDITURES BEING AGGREGATED TO DETERMINE SATISFACTION OF THE
LIMIT. IN NO EVENT SHALL ANY SUPPLIERS OF MATRITECH BE LIABLE TO CYTOGEN FOR ANY
DIRECT, INDIRECT, CONSEQUENTIAL OR OTHER DAMAGES ARISING OUT OF THIS AGREEMENT,
AND CYTOGEN AGREES TO PURSUE ANY CLAIMS THAT IT MAY HAVE SOLELY AGAINST
MATRITECH.

                            ARTICLE X - MISCELLANEOUS

         10.1     Publicity. Either party may publicize or announce this
Agreement and the existence of an arrangement between the parties, provided that
such party shall provide the other party with a copy of any written materials to
be used therefor sufficiently prior to publication for the other party to
comment on and make reasonable changes thereto. Except as permitted under
Section 5.10 hereof, neither party shall use the other party's name, trademarks
or service marks without the other party's prior written consent.

         10.2     Assignment. Neither this Agreement nor any of the rights or
obligations hereunder may be assigned by either party without the prior written
consent of the other party; provided however, such restriction shall not apply
in event of a merger, acquisition or sale of substantially all the assets of the
party that are required to perform such party's obligations under this
Agreement.

         10.3     Governing Law and Jurisdiction. This Agreement shall be
governed by and interpreted in accordance with the laws of the Commonwealth of
Massachusetts without regard to its conflict of law principles. Any lawsuit
shall be brought in the federal district court in Boston, Massachusetts and
MATRITECH and CYTOGEN consent to personal jurisdiction and venue in such courts.
Process may be served on either party by using the notice provisions of Section
10.6 below. The prevailing party in any legal action brought by one party
against the other and arising out of this Agreement shall be entitled, in
addition to any other rights and remedies it may have, to reimbursement for its
expenses, including court costs and reasonable attorneys' fees.

<PAGE>

                                     - 19 -

         10.4     Force Majeure. In the event that either party is prevented
from performing or is unable to perform any of its obligations under this
Agreement due to any act of God; fire; casualty; flood; war; strike; lockout;
failure of public utilities; injunction or any act, exercise, assertion or
requirement of governmental authority, including any governmental law, order or
regulation permanently or temporarily prohibiting or reducing the manufacture,
use or sale of Product; epidemic; destruction of production facilities; riots;
insurrection; inability to procure or use materials, labor, equipment,
transportation or energy sufficient to meet manufacturing needs; or any other
cause beyond the reasonable control of the party invoking this Section 10.4 if
such party shall have used its reasonable best efforts to avoid such occurrence,
such party shall give notice to the other party in writing promptly, and
thereupon the affected party's performance shall be excused and the time for
performance shall be extended for the period of delay or inability to perform
due to such occurrence not to exceed a period of sixty (60) days.

         10.5     Waiver. The waiver by either party of a breach or a default of
any provision of this Agreement by the other party shall not be construed as a
waiver of any succeeding breach of the same or any other provision, nor shall
any delay or omission on the part of either party to exercise or avail itself of
any right, power or privilege that it has or may have hereunder operate as a
waiver of any right, power or privilege by such party.

         10.6     Notices. Any notice or other communication in connection with
this Agreement must be in writing by mail, certified, return receipt requested,
by electronic facsimile transmission or by courier service and shall be
effective when delivered to the addressee at the address listed below or such
other address as the addressee shall have specified in a notice actually
received by the addressor.

                           If to MATRITECH:
                                    330 Nevada Street
                                    Newton, MA 02460
                                    Attention: David L. Corbet, President & COO

                           If to CYTOGEN:
                                    650 College Road East
                                    Princeton, New Jersey 08540
                                    Attention: H. Joseph Reiser, CEO

<PAGE>

                                     - 20 -

                                    With a copy to:

                                    Hale and Dorr, LLP
                                    650 College Road, East
                                    Princeton, New Jersey 08540

                                    Attention: David J. Sorin, Esq.

         10.7     Independent Contractors. The relationship of MATRITECH and
CYTOGEN established by this Agreement is that of independent contractors, and
nothing contained in this Agreement shall be construed to (a) give either party
the power to direct and control the day-to-day activities of the other, (b)
constitute the parties as partners, joint venturers, co-owners or otherwise as
participants in a joint or common undertaking, or (c) allow the parties to
create or assume any obligation on behalf of the other party for any purpose
whatsoever. All financial obligations associated with either party's business
are the sole responsibility of that party. Each party shall be solely
responsible for, and shall indemnify and hold the other party free and harmless
from, any and all claims, damages or lawsuits (including the other party's
reasonable attorneys' fees) arising out of the first party's negligent acts and
the negligent acts of its employees or agents.

         10.8     Entire Agreement. This Agreement contains the full
understanding of the parties with respect to the subject matter hereof and
supersedes all prior understandings and writings relating thereto. In the event
of a conflict between the terms of this Agreement and any attachment, the terms
of this Agreement shall govern. No waiver, alteration or modification of any of
the provisions hereof shall be binding unless made in writing and signed by the
parties by their respective officers thereunto duly authorized. The terms and
conditions on any CYTOGEN purchase orders shall not apply. Any restrictive
endorsement on any check or any instrument of payment to MATRITECH which
purports to alter this Agreement or any of the parties' rights shall be of no
force and effect, and the payee party shall be free to negotiate such checks
notwithstanding such void endorsement.

         10.9     Headings. The headings contained in this Agreement are for
convenience of reference only and shall not be considered in construing this
Agreement.

         10.10    Severability. In the event that any provision of this
Agreement is held by a court of competent jurisdiction to be unenforceable
because it is invalid or in conflict with any law of

<PAGE>

                                     - 21 -

any relevant jurisdiction, the validity of the remaining provisions shall not be
affected. MATRITECH and CYTOGEN agree to replace any invalid provision with a
valid provision which most closely approximates the intent and economic effect
of the invalid provision.

         10.11    Successors and Assigns. This Agreement shall be binding upon
and inure to the benefit of the parties hereto and their successors and
permitted assigns.

         10.12    Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original but all of which
together shall constitute one and the same instrument.

         10.13    Recalls.      MATRITECH will be party to effect a recall if
ordered to by the government.

         IN WITNESS WHEREOF, the parties hereto have caused this Distribution
Agreement to be executed as a sealed instrument in their names by their properly
and duly authorized officers or representatives as of the date first above
written.

                                   MATRITECH, INC.

                                   By: /s/ David L. Corbet
                                       ---------------------------------
                                   Title: President

                                   CYTOGEN CORPORATION

                                   By: H. Joseph Reiser
                                       ---------------------------------
                                   Title: President and Chief Executive Officer

<PAGE>

                                     - 22 -

                                  ATTACHMENT A
                                 MARKETING PLAN

         CYTOGEN & MATRITECH RESPONSIBILITIES

RESPONSIBILITIES OF CYTOGEN:

                  -    All marketing, promotion and distribution of Products
                       within the Territory

                  -    Sampling

                  -    Maintaining adequate Products inventories

                  -    Customer and technical service

RESPONSIBILITIES OF MATRITECH:

                  -    Assure Products comply with all claims in its labeling

                  -    Assistance in technical service, clinical marketing and
                       registration

                  -    Securing both a monitoring and diagnoses regulatory
                       approval in the United States

                  -    Assistance with securing necessary reimbursement for the
                       Products

                  -    [**]

                  -    Assist in the performance of an outcome study for the
                       Products.<PAGE>

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                                Exhibit No. 10.22
                Exclusive License and Exclusive Supply Agreement

         This Agreement is made on 20th day of November, 2002 by and between
Matritech, Inc. ("Matritech"), a Delaware corporation having a principal place
of business at 330 Nevada Street, Newton, Massachusetts 02460, U.S.A., and
Sysmex Corporation ("Sysmex"), a Japanese corporation having a principal place
of business at 1-5-1, Wakinohama-kaigandori, Chuo-ku, Kobe, Hyogo 651-0073,
Japan.

         WHEREAS, Matritech has identified certain monoclonal antibodies, called
NMP 179 antibodies, and has proprietary technology in producing and using such
antibodies for the detection of cervical cancer.

         WHEREAS, Sysmex has substantial expertise in the development of
apparatus for medical diagnostics, especially in the automated cellular analysis
areas.

         WHEREAS, Matritech and Sysmex ("the Parties") have been engaged in an
effort for the research, development, commercialization and marketing of a
cervical cancer assessment product.

                                       1

<PAGE>

         WHEREAS, in furtherance of the Parties' effort, the Parties desire that
Matritech provide Sysmex with exclusive supply of the NMP 179 antibodies and the
exclusive worldwide exploitation rights to market, distribute, sell and service
such a cervical cancer assessment product.

         NOW, THEREFORE, in consideration of the promises and mutual covenants
contained herein, the Parties agree as follows:

                               Part I: Definitions

1.       Throughout this Agreement, the following defined terms shall have the
meanings set forth below:

         1.1      "Customers" shall mean an end use customer of Sysmex who
purchases, or is assigned or transferred a Licensed Product from Sysmex through
a legitimate transaction and uses the Licensed Product in the Field.

         1.2      "Field" shall mean the field of [**].

         1.3      "Licensed Methods" shall mean any and all methods the practice
of which would, in the absence of the license granted hereunder, infringe a
Valid Claim of a Licensed Patent.

         1.4      "NMP 179 antibodies" shall mean [**], called NMP 179 antigens,
produced by Matritech as the raw material of NMP 179 Reagents, and any
improvements thereof.

                                       2

<PAGE>

         1.5      "NMP 179 Reagents" shall mean the reagents used in the Field
which include, but are not limited to, [**].

         1.6      "Licensed Patents" shall mean United States Patent Nos.
5,858,683 and 6,027,905, their foreign counterparts, all reissues and
reexaminations of these United States and foreign patents and all patents that
may issue from patent applications derived from any of the foregoing patents,
including continuations, continuation-in-part applications, divisions, renewals
and extensions of any of the foregoing patent applications and patents.

         1.7      "Licensed Products" shall mean any and all products the
manufacture, use, sale, offer for sale or import of which would, in the absence
of the license granted hereunder, infringe a Valid Claim of a Licensed Patent.

         1.8      "Sysmex" shall mean Sysmex Corporation and its affiliates
which shall mean a corporation performing activities relating to Sysmex's
business in which Sysmex owns and controls, directly or indirectly, at least
fifty percent (50%) of the outstanding shares entitled to vote for the Board of
directors and which agree in writing to be bound by the terms of this Agreement.

         1.9      "Net Sales Value" shall mean [**].

         1.10     "Non-Affiliates" shall mean a company or person other than
Sysmex.

                                       3

<PAGE>

         1.11     "Valid Claim" shall mean a pending, issued or unexpired patent
claim included among the Licensed Patents so long as such claim has not been
irrevocably abandoned or held to be invalid in an unappealable decision of a
court or other authority of competent jurisdiction.

                            Part I: Exclusive Supply

2.       Exclusive Supply

         2.1      Upon Sysmex's purchase orders, Matritech agrees to manufacture
and sell all NMP 179 antibodies ordered by Sysmex to Sysmex. Sysmex agrees to
purchase such NMP 179 antibodies solely from Matritech pursuant to the terms and
conditions of this entire Agreement. There is no [**] purchase requirement.

         2.2      Matritech agrees that it will not sell NMP 179 antibodies,
whether sold by Matritech itself or sold by a licensee, distributor or any other
third party authorized by Matritech, to any third party in the Field.

         2.3      Sysmex agrees that for so long as Matritech manufactures and
sells the ordered supply of NMP 179 antibodies to Sysmex, and Part I of this
Agreement is effective, Sysmex will fill all of its requirements under this
Agreement including those for NMP 179 antibodies with NMP 179 antibodies
purchased from Matritech.

                                       4

<PAGE>

3.       Order and Purchase

         3.1      All purchases and sales of NMP 179 antibodies between
Matritech and Sysmex shall be initiated by Sysmex's issuance of written purchase
orders sent via airmail or by facsimile. The acceptance by Matritech of a
purchase order from Sysmex shall be indicated by written acknowledgement thereof
by Matritech.

         3.2      Sysmex shall have the right to cancel its purchase order or
any portions thereof for any reason at any time before the purchase order is
accepted pursuant to Subsection 3.1. Sysmex may not cancel its purchase order or
any portions thereof after it is accepted pursuant to Subsection 3.1 unless the
Parties agree on such cancellation.

4.       Delivery, Shipping and Forecasting

         4.1      Provided the purchase order had been reasonably accurately
forecasted [**] days in advance per Section 4.3, Matritech shall use its best
efforts to ship to Sysmex the ordered NMP 179 antibodies within [**] days after
receiving a purchase order from Sysmex. Matritech will use its best efforts to
ship to Sysmex in such a manner as specified by [**]. All shipping costs shall
be paid by Sysmex.

                                       5

<PAGE>

         4.2 After the ordered NMP 179 antibodies leave the place of manufacture
and prior to delivery to Sysmex, [**] shall be responsible for and shall bear
any and all risk of loss of or damages to the NMP 179 antibodies.

         4.3 Sysmex shall provide Matritech with a unit forecast for the
following [**] months by the first of every three month interval. This is to be
Sysmex's good faith best estimate of their requirements for NMP 179 antibodies
and is not an irrevocable commitment to purchase.

5.       Quality and Inspection

         5.1      Matritech agrees to meet, for every purchase order from
Sysmex, mutually acceptable predetermined requirements on the quality of NMP 179
antibodies.

         5.2      Matritech agrees that all NMP 179 antibodies manufactured and
delivered by Matritech shall be subject to receiving inspection by Sysmex.

         5.3      Within [**] days of the date of delivery of ordered NMP 179
antibodies to Sysmex, including an order repaired or replaced under this
Subsection, Sysmex shall inspect the received order for satisfaction of the
required quality, damage incurred during shipping and conformity to the purchase
order. If Sysmex and Matritech mutually agree that the order Sysmex has received
does not satisfy the required quality, conform to

                                       6

<PAGE>

the purchase order or is damaged during shipment, Sysmex shall notify Matritech
in writing within forty five (45) days of the date of the delivery to Sysmex,
and Matritech shall at its own expense repair or replace such order, which shall
be Matritech's sole liability for such non-conformity to quality standards or
damage.

6.       Payment

         6.1      The Parties agree that the purchase price of NMP 179
antibodies Sysmex will pay to Matritech is equal to [**]. Production cost shall
be limited only to direct manufacturing, quality control and quality assurance
costs plus reasonable general and administration expenses allocated in
accordance with the generally accepted accounting principles.

         6.2      The production cost of NMP 179 antibodies shall be determined
by Matritech and verified by Sysmex once a year and used to calculate purchase
prices of Subsection 6.1 for a twelve-month period to come until it is replaced
by a new production cost determined and approved for the next twelve-month
period.

         6.3      The twelve-month period as set forth in Subsection 6.2 begins
from January 1 and ends on December 31 of the same year. The production cost
used to calculate purchase prices of Subsection 6.1 is a production cost that is
valid when the purchase order is placed by Sysmex provided the requested
delivery date on such purchase order is sixty (60) days or less.

                                       7

<PAGE>

         6.4      By thirty (30) days before January 1 every year, Matritech
shall determine its production cost of NMP 179 antibodies used to calculate
purchase prices of Subsection 6.1 for a next twelve-month period and notify it
to Sysmex, along with appropriate documentation on which the determination of
the production cost is based.

         6.5      Within [**] days subsequent to the end of the thirty-day time
period set forth in Subsection 5.3, Sysmex shall make a payment to a purchase
order through a wire-transfer to the designated bank account.

         6.6      An amount of payment made pursuant to Subsection 6.5 shall be
equal to the purchase price determined pursuant to Subsections 6.1-6.4. Deducted
from the payment are any taxes withheld according to the United States-Japan
Income Tax Treaty (the "Treaty") provided that Sysmex uses its reasonable best
efforts to reduce its withholding obligation pursuant to the Treaty. If Sysmex
withholds any taxes according to the tax treaty, Sysmex shall provide Matritech
with an official certificate of such taxes withheld issued by the appropriate
authority of the Japanese government and any other information that Matritech
may reasonably request concerning the taxes withheld.

7.       Term of Part I of this Agreement

                                       8

<PAGE>

         7.1      Unless terminated earlier pursuant to this Agreement, Part I
of this Agreement shall continue in force until all of the Licensed Patents
expire or become no longer legally effective. Following such period the Part I
of this Agreement will automatically renew for another one year unless either
party gives a 60-day advance notice in writing advising the other party that it
will not renew Part I of this Agreement.

         7.2      Unless the entire Agreement is terminated pursuant to this
Agreement, Part I of this Agreement shall survive expiration or termination of
Part II of this Agreement.

8.       Stable and Sufficient Supply

         8.1      Matritech shall provide stable and sufficient supply of NMP
179 antibodies to Sysmex.

         8.2      If Matritech fails to provide Sysmex with all its required
supply of reasonably accurately forecasted NMP 179 antibodies ordered pursuant
to Part I of this Agreement on any particular purchase order, following written
notice and a reasonable period of cure, such failure may constitute a reason for
Sysmex to terminate Part I of this Agreement.

         8.3      If Part I of this Agreement is terminated for Matritech's
failure to supply NMP 179 antibodies in accordance with Part I of this
Agreement, Sysmex shall be entitled to obtain from Matritech the entire cell
line (hybridoma),

                                       9

<PAGE>

protocols and technologies for producing NMP 179 antibodies without further
consideration. In the event that Matritech fails to supply NMP 179 antibodies
and Sysmex obtains the hybridoma for producing NMP 179 antibodies, then
Matritech will no longer be entitled to the payments described in Section 6 but
will remain entitled to all other payments and royalties described in this
Agreement.

         8.4      Matritech agrees to place the entire cell line (hybridoma) and
protocols into the possession of a mutually agreeable third party escrow service
which will transfer the cell line and the protocols to Sysmex in the event set
forth in Subsection 8.3. To this effect, Matritech and Sysmex shall prepare and
execute an escrow agreement within a reasonably short time after the execution
of this Agreement. The escrow agreement executed by the parties shall be
attached to this Agreement and become part of this Agreement.

                      Part II: EXCLUSIVE LICENSE AGREEMENT

9.       Exclusive License

                                       10

<PAGE>

         9.1      Matritech hereby grants Sysmex the sole and exclusive
worldwide license under the Licensed Patents to: (a) make, have made, use, sell,
offer to sell, lease or otherwise dispose of Licensed Products in the Field; (b)
practice a Licensed Methods in the Field; and (c) sell products or parts for use
in practicing a Licensed Methods in the Field.

         9.2      Matritech represents and agrees that it has not and will not
grant any third parties a license within the Field under any of the Licensed
Patents before Part II of this Agreement becomes no longer effective or is
terminated.

         9.3      The exclusive license granted to Sysmex under Subsection 9.1
includes the right to sublicense provided that (i) granting of such sublicense
has to be approved in advance by Matritech and (ii) sublicensees granted such
sublicense will not market NMP 179 Reagents so as not to affect Matritech
absolute revenues under this Agreement. Besides sublicenses expressly granted by
Sysmex under this subsection, sale, assignment or transfer of a Licensed
Product, or a product or part for use in practicing a Licensed Method, through a
legitimate transaction from Sysmex to a Customer and a Non-Affiliate will carry
the right for the Customer to use the Licensed Product or the product or part,
free of infringement claims under any of the Licensed Patents and the right for
the Non-Affiliate to resell the Licensed Product or the product or

                                       11

<PAGE>

part, free of infringement claims under any of the Licensed Patents.

         9.4      Matritech agrees that under any patents that Matritech has
licensing rights to other than the Licensed Patents owned by Matritech, or
assigned or transferred from Matritech that are or will necessarily be infringed
by use of a Licensed Product or practice of a Licensed Method, Sysmex shall have
a non-exclusive, royalty-free, non assignable or transferable license for the
terms of such patents to the extent that Sysmex exercises its rights granted
under the Licensed Patents pursuant to Subsection 9.1. Matritech further agrees
that under the same patents, the sublicensees who have a sublicense pursuant to
Subsections 9.3 and the Customers and the Non-Affiliates as described in the
same Subsection shall have a non-exclusive, royalty-free, no assignable or
transferable license for the term of the patents to the extent that the
sublicensees exercise its rights granted under the sublicenses.

         9.5      Matritech agrees to assist Sysmex in recording the existence
of the exclusive licenses granted to Sysmex under Subsection 9.1 at the Patent
Office in countries in relation to the Licensed Patents according to the
applicable recordation laws and rules of the countries.

                                       12

<PAGE>

10       Royalties

         10.1     Sysmex shall pay to Matritech [**] percent ([**]%) of the Net
Sales Value.

         10.2     Sysmex shall keep and maintain a record on sales of NMP 179
Reagent to Non-Affiliates and prepare, from the record kept and maintained under
this Subsection, a quarterly report showing the sales of NMP 179 Reagent during
each of three-month periods starting from January 1 and ending on December 31 of
the same year. Sysmex shall provide a quarterly report prepared under this
Subsection to Matritech on or before the 30th day of the first month after each
three-month period ends.

         10.3     Concurrent with providing a quarterly report to Matritech
pursuant to Subsection 10.2, Sysmex shall make a payment through a wire-transfer
to the designated bank account.

         10.4     An amount of payment made pursuant to Subsection 10.3 shall be
equal to [**]% of the Net Sales Value determined in a quarterly report as set
forth in Subsection 10.2. Deducted from a payment are any taxes withheld
according to the Treaty. If Sysmex withholds taxes according the tax treaty,
Sysmex shall provide Matritech with an official certificate of such taxes
withheld issued by the appropriate authority of the

                                       13

<PAGE>

Japanese government and any other information that Matritech may reasonably
request concerning the taxes withheld.

11.      Patent Filing and Maintenance

         Matritech will be primarily responsible at its own expense for the
preparation, filing, prosecution and maintenance of all patent applications and
patents within the Licensed Patents. Matritech shall keep Sysmex informed of the
progress of all patent applications within the Licensed Patents, and shall give
Sysmex reasonable opportunity to comment on the type and scope of useful claims,
patent filings, and prosecution strategy.

12.      Infringement of the Licensed Patents by Third Parties

         12.1     Each party shall notify the other within thirty (30) days of
obtaining knowledge of a possible infringement of the Licensed Patents in the
Field.

         12.2     Matritech shall have the sole right, but not the obligation,
at its own expense, to take all steps that, in Matritech's sole discretion, are
necessary or appropriate to protect and to enforce any of the Licensed Patents
in the Field, including the initiation of legal proceedings against any third
party who has infringed or ever infringes any Licensed Patents within the Field.
Any damage, cost, award fee, recovery, or

                                       14

<PAGE>

compensation paid by any third party in connection with any proceeding initiated
or carried on at Matritech's expense (whether by way of settlement or otherwise)
shall be retained by Matritech. Matritech shall not enter into any settlement,
consent judgment, or any other voluntary final disposition of any infringement
action under this section without the prior written consent of Sysmex, which
consent shall not be unreasonably withheld, conditioned or delayed.

         12.3.    In the event that Matritech elects not to initiate legal
proceedings under section 12.2, Matritech shall provide prompt written notice of
such to Sysmex, and Sysmex shall have the right, but not the obligation, to
initiate legal proceedings against the infringer in the Field at Sysmex's sole
expense, naming Matritech as a party, if so required by law. Matritech agrees to
become a named party of such legal proceedings if so requested by Sysmex. Any
damage, cost, award fee, recovery, or compensation paid by any third party in
connection with any proceeding initiated or carried on at Sysmex's expense
pursuant to this section (whether by way of settlement or otherwise) shall be
retained by Sysmex. Sysmex shall not enter into any settlement, consent
judgment, or any other voluntary final disposition of any infringement action
under this section without the prior written consent of

                                       15

<PAGE>

Matritech, which consent shall not be unreasonably withheld, conditioned or
delayed.

         12.4     In the event that any party ("Initiating Party") desires to
initiate, initiates, or carries on any legal proceeding to enforce or to protect
any of the Licensed Patents under sections 12.2 and 12.3, the other party
(Non-initiating Party) hereto shall fully co-operate with and will supply all
assistance reasonably requested by the initiating party. The Initiating Party
shall have sole control of the proceeding and shall bear reasonable expenses
(excluding legal fees) incurred by the Non-initiating Party in providing such
assistance and cooperation as the Initiating Party may request. The
Non-initiating Party shall be entitled to participate in any proceedings
initiated or carried on by the Initiating Party with counsel selected by it, but
at its own expense.

13.      Term of Part II of this Agreement

         13.1     Unless terminated earlier pursuant to this Agreement, Part II
of this Agreement shall continue in force until all of the Licensed Patents
expire or become no longer legally effective.

         13.2     Unless the entire Agreement is terminated pursuant to this
Agreement, Part II of this Agreement shall survive expiration or termination of
Part I of this Agreement.

                                       16

<PAGE>

14.      Election To Continue Under this Agreement

         In the event that Matritech seeks or is involuntarily placed under the
protection of the bankruptcy laws, Title XI, U.S. Code, and the trustee rejects
this Agreement, Sysmex hereby elects, pursuant to section 365(n) to retain all
rights granted to it under this Agreement to the extent permitted by law.

                          Part III: General Provisions

15.      Applicability of Part III of this Agreement

         Except as specified otherwise, Part III of this Agreement applies to
the entire Agreement including Part I and Part II of this Agreement.

16.      Other Payments

         16.1(a)           In addition to the payments made from Sysmex to
Matritech pursuant to the other sections of this Agreement, Sysmex shall make
the following payments to Matritech:

         (i)      Sysmex shall subscribe newly issued shares of common stock of
Matritech at a premium of 33% over the Market

                                       17

<PAGE>

Price. The "Market Price" shall mean the average of the closing prices of
Matritech's common stock on the NASDAQ (stock market) for the period between
October 15 and November 15 of 2002. The total amount subscribed and paid in by
Sysmex under this Subsection shall be $2,000,000 and it shall be due upon
signing the Agreement. Upon receipt of the amount of $2,000,000, Matritech shall
deliver to Sysmex the share certificate representing the number of shares (the
"Shares") calculated accordingly; by dividing (X) $2,000,000 by (Y) the product
of 1.33 times the Market Price. The stock purchase under this Subsection shall
be subject to Sysmex's conducting the necessary due diligence

         (ii)     Sysmex shall pay $[**] upon United States Food and Drug
Administration's first approval for the Licensed Products for detecting and
assessing cervical cancer on a [**] basis; and

         (iii)    Sysmex shall pay $[**] on the three-year anniversary of the
date when Sysmex launches its marketing of the Licensed Products, or on the date
when Sysmex achieves its sales of the Licensed Products over $[**], whichever
comes first.

         16.1(b)           Sysmex hereby represents and warrants to Matritech,
on behalf of itself and any affiliate that may be acquiring the Shares, that:

                                       18

<PAGE>

         (i)      it is an "accredited investor" within the meaning of Rule 501
promulgated under the Securities Act of 1933, as amended (the "Securities Act")
and was not organized for the specific purpose of acquiring the Shares;

         (ii)     it has sufficient knowledge and experience in investing in
companies similar to Matritech so as to be able to evaluate the risks and merits
of its investment in Matritech and it is able financially to bear the risks
thereof;

         (iii)    it has had an opportunity to (a) discuss Matritech's business,
management and financial affairs with Matritech's management, (b) ask questions
and receive answers concerning the terms of the issuance of the Shares and (c)
obtain any additional information it desires concerning Matritech that Matritech
possesses or can acquire without unreasonable effort or expense;

         (iv)     the Shares being purchased by it are being acquired for its
own account for the purpose of investment and not with a view to or for sale in
connection with any distribution thereof;

         (v)      it understands that (a) the Shares have not been registered
under the Securities Act by reason of their issuance in a transaction exempt
from the registration requirements of the Securities Act pursuant to Section
4(2) thereof or pursuant to Rules 505 or 506 promulgated under the Securities
Act, (b)

                                       19

<PAGE>

the Shares must be held indefinitely unless a subsequent disposition thereof is
registered under the Securities Act or is exempt from such registration, (c) the
Shares will bear a legend to such effect and (d) Matritech will make a notation
on its transfer books to such effect.

         16.1(c)           Sysmex agrees, without the prior written consent of \
Matritech, not to sell, offer to sell, contract to sell, transfer or otherwise
dispose of:

         (i)      [**] of the Shares prior to approval by the United States Food
and Drug Administration, as described above in Section 16.1(a)(ii); or

         (ii)     more than [**] of the Shares prior to the achievement of the
milestone described in section 16.1(a)(iii).

After the achievement of the milestone in section 16.1(a) (iii) or if the entire
Agreement is terminated by either party , Sysmex shall be permitted to sell,
offer to sell, contract to sell, transfer or otherwise dispose of any or all of
the Shares, subject only to compliance with applicable securities laws. If
Sysmex is unable at any time to sell such number of Shares as may be permitted
under this Agreement by reason of restrictions on resale under U.S. securities
laws, Matritech will use its best efforts to register such Shares at Matritech's
expense, under the Securities Act for resale by Sysmex.

                                       20

<PAGE>

         16.2     In addition to the payments made from Sysmex to Matritech
pursuant to Subsection 16.1 and the other sections of this Agreement, Sysmex
shall pay Matritech a minimum of $[**] per quarter for services of development
whether or not such services are rendered for a time period starting from the
effective date of this Agreement through the date when marketing of the Licensed
Products is launched in the United States. Matritech agrees to render such
services as reasonably requested by Sysmex. Sysmex will pay Matritech, at a
reasonable rate, any quarterly cost expended by Matritech in excess of $[**] for
services of development, provided that such services are rendered with Sysmex's
advance authorization.

17.      Warranties, Limits of Liability, Indemnification, and Insurance

         17.1     Matritech warrants that to the best of its knowledge, it has
the power to enter into this Agreement and that it has no knowledge of any
action or claim instituted or threatened by a third party against any of the
Licensed Patents.

         17.2     Matritech further warrants that, to the best of its knowledge,
the NMP 179 antibodies actually provided by Matritech do not infringe any
patent, copyright, trademark or other intellectual property right of any third
party in existence on the date of execution of this Agreement.

                                       21

<PAGE>

         17.3     EXCEPT AS SPECIFICALLY SET FORTH IN SECTIONS 17.1 and 17.2,
MATRITECH MAKES NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, EXPRESS OR IMPLIED,
REGARDING (1) THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, OR (2) THE
VALIDITY, ENFORCEABILITY OR SCOPE OF THE LICENSED PATENTS. ALSO, EXCEPT AS
SPECIFICALLY SET FORTH IN SECTIONS 17.1 AND 17.2, MATRITECH SPECIFICALLY
DISCLAIMS ANY IMPLIED WARRANTIES OF NON-INFRINGEMENT, MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE.

         17.4     MATRITECH'S TOTAL LIABILITY ARISING OUT OF THIS AGREEMENT
SHALL BE LIMITED TO THE AMOUNT HAVING THEN ACTUALLY BEEN PAID BY SYSMEX TO
MATRITECH UNDER THIS AGREEMENT. IN NO EVENT SHALL MATRITECH BE LIABLE TO SYSMEX
OR ANY OTHER ENTITY FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL,
MULTIPLE, PUNITIVE OR OTHER DAMAGES, HOWEVER CAUSED AND ON ANY THEORY OF
LIABILITY, AND WHETHER OR NOT FOR BREACH OF CONTRACT, NEGLIGENCE OR OTHERWISE,
AND WHETHER OR NOT MATRITECH HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.
THESE LIMITATIONS WILL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF
ANY LIMITED REMEDY PROVIDED HEREIN. MATRITECH'S LIMITATION OF LIABILITY IS
CUMULATIVE, WITH ALL OF MATRITECH'S EXPENDITURES BEING AGGREGATED TO DETERMINE
SATISFACTION OF THE LIMIT.

         17.5     Sysmex shall defend, indemnify and hold harmless Matritech,
its directors, officers, employees, and agents and

                                       22

<PAGE>

their respective successors, heirs and assigns from and against any and all
claims, demands, suits, actions, or proceedings brought by any third party (i)
arising out of product liability and personal injury, death and/or property
damage in connection with the use of a Licensed Product or (ii) based on a claim
that the Licensed Product, or the use or sale thereof by Sysmex under this
Agreement infringes any patent, copyright, tradesecret, trademark, or other
intellectual property right of any third party. Sysmex, however, shall not be
required to defend, indemnify and hold harmless Matritech, or any other
indemnified party, to the extent such claims, demands, suits, actions or
proceedings are determined with finality by a court of competent jurisdiction to
have resulted from the negligent, reckless or intentional act or omission of
Matritech or any other indemnified party. Such indemnity obligation is
contingent on prompt written notice of any claim, action or demand for which
indemnity is claimed, reasonable co-operation (at Sysmex's expense) of Matritech
in such defense, and complete control of the defense and settlement thereof,
except that Sysmex will not have the right to make any monetary settlement or
take any other action which would include any admission of liability on the part
of Matritech its directors, officers, employees, and agents and their respective
successors, heirs and assigns without the prior written consent

                                       23

<PAGE>

of the party involved, which consent shall not be unreasonably withheld or
delayed.

         17.6     The parties agree that at least [**] prior to the date any
Licensed Product or Licensed Method is used in human clinical trial for FDA
submission, the parties shall negotiate in good faith and agree upon the terms
of a commercial, general liability insurance policy to protect Matritech with
regard to the events described in Subsection 17.5

18.      Term of the entire Agreement

         18.1     The entire Agreement shall become effective upon the date
first appearing above and, except as otherwise terminated earlier pursuant to
this Agreement, shall continue in force until both Part I and Part II of this
Agreement expire or are terminated.

         18.2     If one of Part I and Part II of this Agreement expires or is
terminated, or otherwise loses its legal effect, the other part may be
terminated with the consent of the Parties.

         18.3     Sysmex is to use its best efforts in bringing Licensed
Products to market. If Sysmex is unable to bring Licensed Products to the United
States market by the end of [**], Matritech and Sysmex will in good faith
discuss any extension

                                       24

<PAGE>

of time at the end of [**] as long as Sysmex has been diligently working on
bringing Licensed Products to the market.

19.      Termination

         19.1     Except as otherwise provided herein, this Agreement may be
terminated by written agreement of both Parties signed by their authorized
officers or representatives.

         19.2     If one of the Parties becomes the subject of a voluntarily or
involuntarily petition in bankruptcy or any proceeding relating to insolvency,
receivership, liquidation or composition of the benefit of creditors, which
petition or proceeding is not dismissed with prejudice within sixty (60) days
after filing, the other Party may terminate Part I, Part II or both Part I and
Part II at its option.

         19.3     If one of the Parties breaches any material term or condition
of this Agreement and fails to cure that breach within sixty (60) days after
receiving written notice of the breach, the non-breaching Party may terminate
the entire Agreement. The terminating party shall have all rights and remedies
available at law or equity as well as any other rights and remedies set forth in
this Agreement.

20.      Confidential Information

                                       25

<PAGE>

         20.1     For purpose of hereof, the term "Confidential Information" as
applicable to each Party shall mean all business and financial information
relating to that Party, all proprietary information relating to the Licensed
Patents and any products or processes produced in connection with the Licensed
Patents, and all inventions, discoveries, methods, plans, techniques, processes,
documents, drawings, data, samples, patent applications, trade secrets,
know-how, and information of the applicable party that is related thereto and
marked "Confidential."

         20.2     The Confidential Information shall not include anything that:

         (i)      is or lawfully becomes in the public domain, other than as a
result of a breach of an obligation hereunder;

         (ii)     is furnished to the recipient by a third party having a lawful
right to do so; or

         (iii)    was known to the recipient at the time of the disclosure.

         20.3     Each Party hereto shall for the term of this entire Agreement
and for a period of two years thereafter:

         (i)      treat as confidential and preserve the confidence of all
Confidential Information of the other party;

                                       26

<PAGE>

         (ii)     make no use of the other Party's Confidential Information
except as expressly permitted under this Agreement; and

         (iii)    limit access to the other Party's Confidential Information to
the recipient's employees who reasonably require access to such Confidential
Information.

         20.4     Upon termination of the entire Agreement, each party shall
promptly deliver to the other Party all tangible embodiments, including all
copies, of the other Party's Confidential Information; provided, however, that
each party shall be entitled to keep one copy of such Confidential Information
as necessary for proper business purposes as long as it continues to follow the
confidentiality obligations under this Section.

         20.5     There is not an adequate remedy at law for a breach of this
Section, and Matritech or Sysmex will suffer irreparable harm as a result of
such a breach. Therefore, if a breach or threatened breach by either Party of
this Section occurs, in addition to any other rights and remedies it may have,
the non-breaching party shall be entitled to injunctive relief restraining the
breaching party from doing any act in violation of this Section without the
requirement of posting bond, cash or otherwise.

                                       27

<PAGE>

21.      Intellectual Property

         The Parties agree that any intellectual property, including without
limitation inventions, discoveries, designs, trade secrets, know-how and other
forms of proprietary information, that is made, created, or developed solely by
one Party in relation to any of the Licensed Patents, the Licensed Methods and
the Licensed Products will belong to such one Party.

22.      Survival

         The provisions of this Agreement that, by their sense and context are
intended to survive performance by either or both Parties, shall also survive
the completion, expiration, termination or cancellation of this Agreement.

23.      Successors and Assigns

         Neither party shall assign this Agreement or any of the rights,
interests or obligations hereunder either in whole or in part, without the prior
written consent of the other party hereto, except that Matritech's rights and
obligations under this agreement may be assigned to any entity that acquires
substantially all of the business relating to this Agreement, which entity shall
agree in writing to be bound by the terms of this Agreement.

                                       28

<PAGE>

24.      No joint venture

         Nothing contained in this Agreement shall be deemed or construed as
creating a joint venture or partnership between the Parties. Neither party shall
have the power to control the activities or operations of the other party.
Neither party shall hold itself out as having authority or relationship in
contravention of this Section.

25.      Entire Agreement

         This Agreement constitutes the entire agreement between the Parties
relating the subject matter thereof. All prior or contemporaneous agreements,
whether written or oral, between the Parties, or their agents and
representatives to the subject hereof are merged into this Agreement. This
Agreement may be altered or amended only by an instrument in writing signed by
all the Parties hereto.

26.      Severability

         If any term or provision of this Agreement shall, to any extent, be
determined to be invalid or unenforceable by a court or body of competent
jurisdiction, the reminder of this Agreement shall not be affected thereby, and
each term and provision of this Agreement shall be valid and enforceable to the
fullest extent permitted by law.

                                       29

<PAGE>

27.      Applicable Law

         The validity, interpretation, enforceability and performance of this
Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, U.S.A. without regard to the conflicts of law
principles.

28.      Settlement of Dispute

         28.1     The Parties shall confer in good faith to attempt to resolve
any disputes or controversies arising out of or relating to this Agreement and
attempt to negotiate any term, condition, right or obligation not set forth in
this Agreement.

         28.2     If such attempt fails, all matters of concern shall be
submitted to Arbitration, which shall be conducted either in Boston,
Massachusetts if Sysmex requests such Arbitration or in Osaka, Japan if Matitech
requests such Arbitration by a panel of three arbitrators pursuant to the rules
of the International Chamber of Commerce and shall be final and binding on all
the parties.

29.      Force Majeure

         Neither party shall be liable for delay or failure in the performance
of its obligations hereunder if such delay or

                                       30

<PAGE>

failure arises from the occurrence of evens beyond the reasonable control of
such party, such as fire, flood, earthquake, storm, government regulations or
the intervention of any government authority. In such case, the parties hereto
may confer to alter this Agreement.

30.      Patent Marking

         Sysmex shall apply the patent marking notices in accordance with the
applicable patent laws of countries where Licensed Products are made, sold or
used to the extent commercially feasible as consistent with prevailing business
practices.

31.      The terms of this Agreement are confidential and shall not be disclosed
to any third party, except as required by the law or regulations, without the
prior written consent of the other party.

32.      This Agreement may be executed in any number of counterparts, each of
which shall be considered an original, and all of which together shall be deemed
to be one and the same instrument.

MATRITECH, INC.                                      SYSMEX CORPORATION

                                       31

<PAGE>

By: /s/ Stephen D. Chubb                             By: /s/ Hisashi Tetsugu

Print: Stephen d. Chubb                              Print: Hisashi Tetsugu

Title: Director, Chairman,                           Title: President and CEO
       and Chief Executive Officer

                                       32

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}]]